SereNeuro Therapeutics

What SereNeuro Therapeutics does

SereNeuro Therapeutics is a preclinical biotechnology company developing SN101, a first-in-class induced pluripotent stem cell (iPSC)-derived mature, non-dividing nociceptor cell therapy intended to treat chronic osteoarthritis joint pain while simultaneously halting cartilage degeneration. The therapy works by locally absorbing inflammatory pain factors within the joint, contrasting mechanistically with both opioid analgesics and intra-articular corticosteroids — the current standards of care, which mask symptoms without modifying disease and carry addiction risk in the case of opioids. The company is targeting chronic pain patients with osteoarthritis who lack disease-modifying, non-opioid options.

The platform originated in the laboratories of co-founders Xinzhong Dong, PhD and Gabsang Lee, PhD DVM at Johns Hopkins University, where the company is headquartered within Johns Hopkins Technology Ventures' FastForward 1812 incubator in Baltimore's Eager Park tech corridor. CEO Dan Saragnese, MBA leads commercialization, with Poppy Wang, PhD also serving as a co-founder and scientific advisor. Preclinical proof-of-concept data were presented at the ISSCR Symposium in Cambridge, Massachusetts in December 2025, and the company is advancing SN101 toward IND-enabling studies.

SereNeuro currently has no commercial revenue and supports development through non-dilutive grant funding (notably the 2025 MSCRF Commercialization Grant) and an early venture investment from Ecphora Capital. The expected revenue model is one-time licensing or partnership-based commercialization with large pharmaceutical companies following FDA approval of SN101. The company is an alumnus of Nucleate Activator and a 2025 graduate of CDL-Toronto's Advanced Therapies stream, and was recognized on BioBuzz's RealLIST Maryland Startups 2026.

Name

SereNeuro Therapeutics

Legal name

SereNeuro Therapeutics

Website

https://sereneuro.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

SereNeuro Therapeutics is a preclinical biotechnology company developing SN101, a first-in-class iPSC-derived nociceptor cell therapy for chronic osteoarthritis pain. The therapy absorbs inflammatory factors locally in joints and halts cartilage degeneration, offering non-opioid, disease-modifying alternatives for patients.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Cell Therapy

NAICS

Offices of Physical, Occupational and Speech Therapists, and Audiologists (621340), Services for the Elderly and Persons with Disabilities (62412)

SIC

Services-Misc Health & Allied Services, Nec (8090), Pharmaceutical Preparations (2834)

akta.pro primary industry

SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)

akta.pro secondary industries

Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Cell therapy development
• Pain management therapeutics
• Stem cell therapy
• Chronic pain treatment
• Osteoarthritis therapeutics

Headquarters

HQ city

Baltimore

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Biopharmaceutical Development & Commercialization: Pre-revenue preclinical biotechnology company developing a first-in-class iPSC-derived cell therapy (SN101). Revenue model expected to be through pharmaceutical commercialization following FDA regulatory approval, likely via licensing or partnership with large pharmaceutical companies for distribution.

Distribution channels1 record

Marketing channels3 records

Core offering

SereNeuro Therapeutics is developing SN101, a first-in-class iPSC-derived cell therapy that uses mature peripheral pain-sensing neurons (nociceptors) to absorb inflammatory pain factors locally within osteoarthritic joints while halting cartilage degeneration. The product is positioned as a non-opioid, disease-modifying alternative to current symptom-focused chronic pain treatments such as corticosteroids and opioids. The company is advancing SN101 through preclinical development toward IND-enabling studies.

Product overview

SereNeuro Therapeutics is a preclinical biotechnology company developing a single lead product, SN101, an iPSC-derived cell therapy for chronic pain management and joint tissue preservation. SN101 uses mature nociceptors to absorb inflammatory pain signals and inhibit cartilage degeneration, representing a first-in-class non-opioid approach to osteoarthritis pain treatment. The company is advancing SN101 toward IND-enabling studies following positive preclinical data presented in December 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• SN101 SN101 is a first-in-class iPSC-derived cell therapy using mature peripheral pain-sensing neurons (nociceptors) to treat chronic osteoarthritis joint pain. The therapy absorbs inflammatory pain factors locally within the joint and halts cartilage degeneration, offering a non-opioid, disease-modifying alternative to current symptom-focused treatments such as corticosteroids and opioids. SN101 is in preclinical development for patients with chronic osteoarthritis pain.

Quantifiable outcome

• Preclinical data presented at ISSCR Symposium demonstrated pain relief and inhibition of cartilage degeneration in osteoarthritis models
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core and minor.

• Creative Destruction Lab (CDL) - TorontocoreStrategic or Co-development PartnerSereNeuro graduated from the 2025 Advanced Therapies stream at CDL-Toronto, a venture mentorship program that supports science-based startups in advancing their technologies toward commercialization.
• Johns Hopkins Technology Ventures (JHTV)coreStrategic or Co-development PartnerSereNeuro is located at FastForward 1812, a JHTV incubator in the Eager Park tech corridor adjacent to Johns Hopkins Hospital. The company was founded by Johns Hopkins faculty members and leverages the university's research infrastructure.
• Nucleate ActivatorminorStrategic or Co-development PartnerSereNeuro is an alumni company of the Nucleate Activator program, a trainee-led nonprofit that helps academic researchers transition from lab discoveries to biotech startups. Being an alumni contributed to recognition on the RealLIST Maryland Startups 2026.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Vertex Pharmaceuticals: Vertex is developing non-opioid pain therapies, most notably VX-548 (a NaV1.8 inhibitor) for acute and chronic pain. It is the most advanced and well-capitalized competitor pursuing a non-opioid pain strategy directly comparable to SereNeuro's SN101.
• Centrexion Therapeutics: Centrexion is a clinical-stage biotech developing non-opioid therapies for chronic pain, with a lead focus on osteoarthritis pain (e.g., CNTX-4975). It directly competes with SereNeuro's target indication and non-opioid positioning.
• Trevena Inc. Trevena develops non-opioid pain therapeutics, including OLINVYK (oliceridine), a Schedule II opioid alternative. It is a direct peer in the non-opioid pain development space with a similar focus on safer pain management.
• BlueRock Therapeutics: BlueRock is a leading iPSC-derived cell therapy developer (acquired by Bayer) working on engineered cell therapies for multiple diseases. It is a direct platform and modality peer to SereNeuro's iPSC-derived cell therapy approach.
• Vericel Corporation: Vericel markets MACI (autologous cultured chondrocytes) for cartilage repair and is developing cell therapies for orthopedic indications. It is directly comparable as a cell therapy company addressing cartilage and joint disease.

Broad incumbents

• Eli Lilly and Company: Lilly co-developed tanezumab (anti-NGF) with Pfizer for chronic osteoarthritis pain and has a broad chronic pain portfolio. It is a broad incumbent pursuing non-opioid pain therapies that could overlap with or compete against SN101 at launch.
• Pfizer Inc. Pfizer has been a major player in chronic pain via tanezumab (anti-NGF) co-development with Lilly and other non-opioid pain programs. As a large incumbent, it represents both a potential competitor and a likely partnership/acquisition target for SereNeuro.
• Regeneron Pharmaceuticals: Regeneron has invested in pain neuroscience through its Regeneron Genetic Medicines and antibody platforms and has historically been active in osteoarthritis and pain pathways. It is a broad incumbent with relevant capabilities in biologic pain therapeutics.

Emerging players

• Century Therapeutics: Century is a clinical-stage iPSC-derived engineered cell therapy company focused on oncology, sharing the iPSC cell therapy modality with SereNeuro. It is a comparable emerging player demonstrating the platform's translational viability, though in a different indication.

Others

• Pacira BioSciences: Pacira commercializes EXPAREL (long-acting non-opioid local anesthetic) and iovera (cryoneurolysis) for postsurgical and chronic pain, positioning it as an adjacent non-opioid pain company. It is thematically related as a non-opioid pain commercializer rather than a direct mechanism competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sereneuro

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SereNeuro Therapeutics